

1-1-1998

Specific Binding and Epitope Recognition in Lectin subtypes

Ayşegül AYYILDIZ

Follow this and additional works at: <https://journals.tubitak.gov.tr/medical>



Part of the [Medical Sciences Commons](#)

Recommended Citation

AYYILDIZ, Ayşegül (1998) "Specific Binding and Epitope Recognition in Lectin subtypes," *Turkish Journal of Medical Sciences*: Vol. 28: No. 2, Article 22. Available at: <https://journals.tubitak.gov.tr/medical/vol28/iss2/22>

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more information, please contact academic.publications@tubitak.gov.tr.

Ayşegül AYYILDIZ

Specific Binding and Epitope Recognition in Lectin subtypes

Department of Biochemistry and Clinical
Chemistry, Faculty of Medicine, Ankara Uni-
versity, Sıhhiye, Ankara-Turkey

Received: March 10, 1998

In hereby congratulate Dr.Şeftalioğlu et al for their work on lectins, on their report of binding of HPL-GC to dog gastric mucin (1) emphasizing the applications of protein and lipid glycosylation which once was considered as a topic whose appeal is restricted to a limited number of analytical biochemistry experts.

However, I would like to mention some points for meticulous planning of their future research, as well as drawing attention to variations of specificity in commercial molecular conjugates, on occasion.

Lectins comprise a structurally very diverse class of proteins characterized by their ability to bind carbohydrates with considerable specificity(2). An epitope, though commonly refers to antigenic determinants could be described in general protein-ligand interaction terms, as an operational definition of a surface area either directly responsible for, or intimately involved in specific molecular interaction(3). Determination of specificity of binding and revelation of binding sites or motifs requires advanced chemical modification or mutational techniques supported by affinity testing which could be done by employing labeling, as an example (4).When talking of a specific epitope, description and evidences should be at molecular level which must have been already described by the supplier (Sigma, UK) as the authors have mentioned as source of HPL-GC.

Moreover as a control for specific recognition in vivo the authors have mentioned using "non-labeled" lectin which obviously wouldn't result in any image. Thus the selection of the internal experimental control is improper for the purpose. Besides no(+) control has been included in the experiment so that the reader could depict the laid stain actually designates N. Acetyl galactosamine (NAG) residues. This could be done by a number of ways among which I could mention using labeled MoAbs that have been shown to recognize NAG residues(5), or O-glycosidase (eg. Boehringer-Mannheim) treatment of the sections to eliminate NAG to distort the molecular integrity to end-up with a change in staining properties which would be significant as the folding properties of molecules could vary in vivo(6).

Traditionally the discussion of an article should contain self-criticism of the obtained data in comparison to relevant research rather than general information from some research in the field. I would suggest, the best reasonable conclusion to depict from the laid data could be HPL-GC stains dog gastric mucosa better than derivations about specific molecular recognition of epitopes. I wish further success with the upcoming studies.

References

1. Şeftalioğlu A, Korkusuz P, Alabay B, Özcan Z. Helix Pomatia Lectin Binding Sites in the Dog Gastric Mucus Layer. *Turk J Med Sci* 27:105-7, 1997.
2. Rini JM. Lectin Structure. *Annu Rev Biophys Biomol Struct* 24:551-7, 1995.
3. Novotny J, Nicholls A. Immunology. Molecular Biology and Biotechnology, A comprehensive Desk Reference (Eds. RA Meyers) VCH Publishers, Inc. New York, USA, 1995, pp. 449-55.
4. Creighton TE. Proteins. Structures and Molecular Properties. W.H. Freeman and Company, New York, 1993, pp. 261-384.
5. Reis CA, Hassan H, Bennett EP, Clausen H. Characterisation of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1. *Tumor Biol* 19 Suppl 1: 127-33, 1998.
6. Johnson JL, Craig EA. Protein folding in vivo: unraveling complex pathways. *Cell* 90:201-4, 1997.